Study identifier:D589LC00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, plus terbutaline Turbuhaler 0.4 mg as needed, for treatment of asthma - a 12-month, randomized, double-blind, parallel group, active-controlled, multinational phase III study in asthmatic patients from 16 years
asthma
Phase 3
No
Symbicort Turbuhaler, Terbutaline Turbuhaler
All
2091
Interventional
16 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy
Location
Location
KOBE-CITY, Hyogo, Japan
Location
AKO, Hyogo, Japan
Location
ASAHI, Chiba, Japan
Location
ASAHIKAWA, Hokkaido, Japan
Location
BANGALORE, Karnataka, India
Location
BANGKOK, Thailand, Thailand
Location
BANGKOKNOI, Bangkok, Thailand
Location
BARRIO SAN BOSCO, SAN JOSE, Puerto Rico
Arms | Assigned Interventions |
---|---|
Experimental: 1 Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed | Drug: Symbicort Turbuhaler 160/4.5 µg |
Active Comparator: 2 Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed | Drug: Symbicort Turbuhaler 160/4.5 µg Drug: Terbutaline Turbuhaler 0.4 mg |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.